Across TCGA pan-cancer cohorts, CCDC159 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCDC159 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CCDC159 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC159 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, OV, and UCEC are the cancer types where CCDC159 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.199	0.768	.002	42	view →
OV	DFS	Median	All	0.254	0.542	.008	18	view →
UCEC	DFS	Median	All	1.000	0.630	.029	14	view →
SCLC	OS	Median	II,III,IV	0.192	0.645	.014	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: CCDC159 tumor-vs-normal RNA expression · all CCDC159 data types